整合[89Zr]Zr-Girentuximab PET-CT表征小肾肿块的成本效益
基于3期ZIRCON试验,本研究用决策分析马尔可夫模型评估65岁偶发小肾肿块患者三种管理策略的成本效益。TLX250-CDx策略可避免57.2%患者活检、未治疗恶性肿瘤风险0.8%,相比部分肾切除术的增量成本效益比为55,779美元/QALY,具成本效益。
要点
- TLX250-CDx策略避免57.2%患者活检,未治疗恶性肿瘤风险仅0.8%。
- 相比部分肾切除术,增量成本效益比为55,779美元/QALY,低于10万美元/QALY阈值。
- 该策略使67.7%良性肿瘤免于治疗,敏感性分析结果稳健。
核心结论
- 使用TLX250-CDx表征小肾肿块并对阴性病例行确认性活检,可避免近60%患者活检、超过三分之二良性肿瘤免于治疗,未治疗恶性肿瘤风险低于1%,相比常规实践可能具成本效益。
研究设计与样本
- 决策分析马尔可夫模型,评估65岁偶发小肾肿块患者的三种管理策略:经验性部分肾切除术(参考组)、肾肿块活检(选项1)、TLX250-CDx后活检确认良性肿瘤(选项2)。
- 从美国Medicare支付方角度,评估终生时间 horizon 内的生命年、质量调整生命年(QALY)和直接医疗成本,以10万美元/QALY为支付意愿阈值,并进行情景和概率敏感性分析。
主要发现
- 选项2的未治疗恶性肿瘤风险为0.8%,参考组为0%,选项1为2.7%。
- 选项2使67.7%良性肿瘤免于治疗,参考组为0%,选项1为70.8%。
- 选项2避免57.2%患者的活检。
- 选项2为最具成本效益策略,名义上优于选项1,相比参考组的增量成本效益比为55,779美元/QALY。
- 结果在敏感性分析中稳健。
临床怎么用
- 对于65岁偶发小肾肿块患者,可考虑使用TLX250-CDx PET-CT表征后对阴性病例行确认性活检,以减少活检和治疗良性肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The phase-3 ZIRCON trial demonstrated the diagnostic utility of [89Zr]Zr-girentuximab positron emission tomography-CT (TLX250-CDx) for detecting clear cell renal cell carcinoma. We evaluated the cost-effectiveness of incorporating TLX250-CDx for small renal mass (SRM) management. MATERIALS AND METHODS: We developed a decision-analytic Markov model to estimate the costs and health outcomes of competing management strategies for patients age 65 years diagnosed with an incidental SRM: empiric partial nephrectomy (reference arm), renal mass biopsy (option 1), and TLX250-CDx, followed by biopsy to confirm benign tumors (option 2). We assessed life-years, quality-adjusted life-years (QALYs), and direct medical costs from a US Medicare payer perspective over a lifetime horizon. We assessed incremental cost-effectiveness ratios against a $100,000/QALY willingness-to-pay threshold. Scenario and probabilistic sensitivity analyses were conducted. RESULTS: Option 2 achieved the lowest risk of untreated malignant tumors (0.8%) besides the reference arm (0% by default; 2.7% for option 1) and a high probability of leaving benign tumors untreated (67.7%, vs 0% for reference, 70.8% for option 1). Option 2 avoided biopsy for 57.2% of patients. Option 2 was the most cost-effective strategy. It nominally dominated option 1 and had an incremental cost-effectiveness ratio of $55,779/QALY vs the reference arm. The results were robust across sensitivity analyses. CONCLUSIONS: Using TLX250-CDx to characterize SRMs followed by confirmatory biopsy of negative cases helps avoid biopsy for nearly 60% of patients and treatment of over two-thirds of benign tumors, minimizes the risk of untreated malignancy (<1%), and is likely cost-effective compared with current conventional practices.
引用
- Kanabur P, Su ZT, Kaba A, et al. Cost-Effectiveness of Incorporating [89Zr]Zr-Girentuximab Positron Emission Tomography-Computed Tomography for Characterizing Small Renal Masses. J Urol. 2026. PMID: 41637489. doi:10.1097/JU.0000000000004912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。